Before sending payment to the scammers, she reached out to NCL
are obese, and about 1 in 13 are severely obese
The optimistic scenario assumes: Higher weight-loss efficacy, based on emerging data from trials of AOMs Expanded access to the drug, driving higher uptake assumptions Higher persistency, driven by reduced costs and oral forms of the drug and fewer side effects Lower weight regain after stopping the drug Higher non-weight-loss-related mortality impacts The pessimistic scenario, conversely, considers lower efficacy, lower uptake assumptions, higher and quicker weight regain, and lower non-weight-loss-related mortality impacts
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of incretin-based therapies, are promising antidiabetic agents
Alt Text: Retatrutide peptide evidence landscape showing obesity, type 2 diabetes, MASLD, safety, and investigational status Full AI Image Prompt: Create a medical editorial infographic titled Retatrutide Evidence Landscape. Design a clean evidence matrix with rows labeled Obesity trials, Type 2 diabetes trials, MASLD substudy, Cardiometabolic markers, and Safety data. Add columns labeled What was studied, Evidence level, and What it can and cannot show. Use concise text blocks such as clinical evidence, early clinical evidence, risk-marker outcomes, and investigational status. Use a white background, thin lines, calm blue and green accents, no people, no syringes, no product imagery, and no guaranteed outcome language
It is available through standard pharmacy channels with a prescription
